Regulatory myeloid cells in transplantation

Transplantation

Volumn 97, Issue 4, 2014, Pages 367-379

  Rosborough, Brian R ^a,b   Raïch Regué, Dàlia ^a   Turnquist, Heth R ^a,b   Thomson, Angus W ^a,b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Immune regulation; Myeloid cells; Transplantation

Indexed keywords

ABATACEPT; ALEMTUZUMAB; AZATHIOPRINE; AZITHROMYCIN; BORTEZOMIB; CALCINEURIN INHIBITOR; CALCITRIOL; CD40 LIGAND MONOCLONAL ANTIBODY; CYCLOOXYGENASE 2 INHIBITOR; CYCLOSPORIN A; DEXAMETHASONE; GLUCOCORTICOID; HISTONE DEACETYLASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY CD28; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OLIGODEOXYNUCLEOTIDE; PREDNISOLONE; PROTEASOME INHIBITOR; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SMALL INTERFERING RNA; TACROLIMUS; THYMOCYTE ANTIBODY; TRICHOSTATIN A; VALPROIC ACID; VORINOSTAT;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIGEN SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ATOPIC DERMATITIS; BONE MARROW CELL; CELL MIGRATION; CELL TRANSPORT; CONTACT ALLERGY; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; DONOR SELECTION; DRUG ANTAGONISM; DRUG TARGETING; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MACROPHAGE; NONHUMAN; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY MYELOID CELL; REVIEW; SKIN ALLOGRAFT; SKIN TRANSPLANTATION; SUPPRESSOR CELL; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; ANTIGENS; CELL CULTURE TECHNIQUES; CELL MOVEMENT; CELL SURVIVAL; CELL TRANSPLANTATION; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; MACROPHAGES; MICE; MYELOID CELLS; RATS; TRANSPLANTATION TOLERANCE;

EID: 84896707953     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182a860de     Document Type: Review

References (176)

1. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004; 4: 378.
2. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715.
3. Wood KJ, Bushell A, Hester J. Regulatory immune cells in transplantation. Nat Rev Immunol 2012; 12: 417.
4. Hutchinson JA, Riquelme P, Geissler EK. Human regulatory macrophages as a cell-based medicinal product. Curr Opin Organ Transplant 2012; 17: 48.
5. Broichhausen C, Riquelme P, Geissler EK, et al. Regulatory macrophages as therapeutic targets and therapeutic agents in solid organ transplantation. Curr Opin Organ Transplant 2012; 17: 332.
6. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245.
7. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271.
8. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21: 685.
9. Belz GT, Nutt SL. Transcriptional programming of the dendritic cell network. Nat Rev Immunol 2012; 12: 101.
10. Hackstein H, Thomson AW. Dendritic cells: Emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004; 4: 24.
11. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610.
12. Stenger EO, Turnquist HR, Mapara MY, et al. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012; 119: 5088.
13. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162.
14. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253.
15. van Kooten C, Lombardi G, Gelderman KA, et al. Dendritic cells as a tool to induce transplantation tolerance: Obstacles and opportunities. Transplantation 2011; 91: 2.
16. Kalantari T, Kamali-Sarvestani E, Ciric B, et al. Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res 2011; 51: 153.
17. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233.
18. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood 2002; 100: 174.
19. Giannoukakis N, Phillips B, Finegold D, et al. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34: 2026.
20. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008; 21: 728.
21. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008; 21: 742.
22. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008; 21: 808.
23. Hutchinson JA, Riquelme P, Sawitzki B, et al. Cutting edge: Immunological consequences and trafficking of human regulatory macrophages administered to renal transplant recipients. J Immunol 2011; 187: 2072.
24. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Semin Immunol 2011; 23: 252.
25. Piemonti L, Monti P, Sironi M, et al. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. J Immunol 2000; 164: 4443.
26. Pedersen AE, Gad M, Walter MR, et al. Induction of regulatory dendritic cells by dexamethasone and 1alpha,25-dihydroxyvitamin D(3). Immunol Lett 2004; 91: 63.
27. Anderson AE, Sayers BL, Haniffa MA, et al. Differential regulation of naive and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol 2008; 84: 124.
28. Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010; 116: 935.
29. Macedo C, Turquist H, Metes D, et al. Immunoregulatory properties of rapamycin-conditioned monocyte-derived dendritic cells and their role in transplantation. Transplant Res 2012; 1: 16.
30. Zahorchak AF, Kean LS, Tokita D, et al. Infusion of stably immature monocyte-derived dendritic cells plus CTLA4Ig modulates alloimmune reactivity in rhesus macaques. Transplantation 2007; 84: 196.
31. Ezzelarab M, Zahorchak AF, Lu L, et al. Regulatory dendritic cell infusion prolongs kidney allograft survival in non-human primates. Am J Transplant 2013; 13: 1989.
32. Moreau A, Varey E, Bouchet-Delbos L, et al. Cell therapy using tolerogenic dendritic cells in transplantation. Transplant Res 2012; 1: 13.
33. Solari MG, Thomson AW. Human dendritic cells and transplant outcome. Transplantation 2008; 85: 1513.
34. Harry RA, Anderson AE, Isaacs JD, et al. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69: 2042.
35. Raich-Regue D, Grau-Lopez L, Naranjo-Gomez M, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012; 42: 771.
36. Boros P, Ochando JC, Chen SH, et al. Myeloid-derived suppressor cells: Natural regulators for transplant tolerance. Hum Immunol 2010; 71: 1061.
37. Marigo I, Bosio E, Solito S, et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 2010; 32: 790.
38. Highfill SL, Rodriguez PC, Zhou Q, et al. Bone marrow myeloidderived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is upregulated by interleukin-13. Blood 2010; 116: 5738.
39. Kusmartsev S, Nagaraj S, Gabrilovich DI. Tumor-Associated CD8+ T cell tolerance induced by bone marrow-derived immature myeloid cells. J Immunol 2005; 175: 4583.
40. Yin B, Ma G, Yen CY, et al. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol 2010; 185: 5828.
41. Zhang W, Liang S, Wu J, et al. Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1+ myeloidderived suppressor cells that promote long-Term survival of allografts. Transplantation 2008; 86: 1125.
42. De Wilde V, Van Rompaey N, Hill M, et al. Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant 2009; 9: 2034.
43. Chou HS, Hsieh CC, Charles R, et al. Myeloid-derived suppressor cells protect islet transplants by B7-H1 mediated enhancement of T regulatory cells. Transplantation 2012; 93: 272.
44. Zhou Z, French DL, Ma G, et al. Development and function of myeloid-derived suppressor cells generated from mouse embryonic and hematopoietic stem cells. Stem Cells 2010; 28: 620.
45. Lechner MG, Liebertz DJ, Epstein AL. Characterization of cytokineinduced myeloid-derived suppressor cells from normal human peripheral blood mononuclear cells. J Immunol 2010; 185: 2273.
46. Obermajer N, Kalinski P. Generation of myeloid-derived suppressor cells using prostaglandin E2. Transplant Res 2012; 1: 15.
47. Riquelme P, Tomiuk S, Kammler A, et al. IFN-gamma-induced iNOS expression in mouse regulatory macrophages prolongs allograft survival in fully immunocompetent recipients. Mol Ther 2013; 21: 409.
48. Riquelme P, Geissler EK, Hutchinson JA. Alternative approaches to myeloid suppressor cell therapy in transplantation: Comparing regulatory macrophages to tolerogenic DCs and MDSCs. Transplant Res 2012; 1: 17.
49. Beriou G, Moreau A, Cuturi MC. Tolerogenic dendritic cells: Applications for solid organ transplantation. Curr Opin Organ Transplant 2012; 17: 42.
50. Larsen CP, Morris PJ, Austyn JM. Migration of dendritic leukocytes from cardiac allografts into host spleens. A novel pathway for initiation of rejection. J Exp Med 1990; 171: 307.
51. Demetris AJ, Murase N, Starzl TE. Donor dendritic cells after liver and heart allotransplantation under short-Term immunosuppression. Lancet 1992; 339: 1610.
52. Yu G, Xu X, Vu MD, et al. NK cells promote transplant tolerance by killing donor antigen-presenting cells. J Exp Med 2006; 203: 1851.
53. Divito SJ, Wang Z, Shufesky WJ, et al. Endogenous dendritic cells mediate the effects of intravenously injected therapeutic immunosuppressive dendritic cells in transplantation. Blood 2010; 116: 2694.
54. Beriou G, Peche H, Guillonneau C, et al. Donor-specific allograft tolerance by administration of recipient-derived immature dendritic cells and suboptimal immunosuppression. Transplantation 2005; 79: 969.
55. Moreau A, Hill M, Thebault P, et al. Tolerogenic dendritic cells actively inhibit T cells through heme oxygenase-1 in rodents and in nonhuman primates. FASEB J 2009; 23: 3070.
56. Hill M, Thebault P, Segovia M, et al. Cell therapy with autologous tolerogenic dendritic cells induces allograft tolerance through interferon-gamma and Epstein-Barr virus-induced gene 3. Am J Transplant 2011; 11: 2036.
57. Movahedi K, Guilliams M, Van den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. Blood 2008; 111: 4233.
58. Nagaraj S, Gupta K, Pisarev V, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 2007; 13: 828.
59. Caquard M, Ferret-Bernard S, Haurogne K, et al. Diabetes acceleration by cyclophosphamide in the non-obese diabetic mouse is associated with differentiation of immunosuppressive monocytes into immunostimulatory cells. Immunol Lett 2010; 129: 85.
60. Youn JI, Nagaraj S, Collazo M, et al. Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 2008; 181: 5791.
61. Obermajer N, Muthuswamy R, Lesnock J, et al. Positive feedback between PGE2 and COX2 redirects the differentiation of human dendritic cells toward stable myeloid-derived suppressor cells. Blood 2011; 118: 5498.
62. Zhu B, Bando Y, Xiao S, et al. CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol 2007; 179: 5228.
63. Lu L, Li W, Fu F, et al. Blockade of the CD40-CD40 ligand pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-Term cardiac allograft survival. Transplantation 1997; 64: 1808.
64. DePaz HA, Oluwole OO, Adeyeri AO, et al. Immature rat myeloid dendritic cells generated in low-dose granulocyte macrophagecolony stimulating factor prolong donor-specific rat cardiac allograft survival. Transplantation 2003; 75: 521.
65. Wang Q, Zhang M, Ding G, et al. Anti-ICAM-1 antibody and CTLA-4Ig synergistically enhance immature dendritic cells to induce donor-specific immune tolerance in vivo. Immunol Lett 2003; 90: 33.
66. Garrovillo M, Ali A, Depaz HA, et al. Induction of transplant tolerance with immunodominant allopeptide-pulsed host lymphoid and myeloid dendritic cells. Am J Transplant 2001; 1: 129.
67. Mirenda V, Berton I, Read J, et al. Modified dendritic cells coexpressing self and allogeneic major histocompatibility complex molecules: An efficient way to induce indirect pathway regulation. J Am Soc Nephrol 2004; 15: 987.
68. Solito S, Bronte V, Mandruzzato S. Antigen specificity of immune suppression by myeloid-derived suppressor cells. J Leukoc Biol 2011; 90: 31.
69. Kerr EC, Raveney BJ, Copland DA, et al. Analysis of retinal cellular infiltrate in experimental autoimmune uveoretinitis reveals multiple regulatory cell populations. J Autoimmun 2008; 31: 354.
70. Marhaba R, Vitacolonna M, Hildebrand D, et al. The importance of myeloid-derived suppressor cells in the regulation of autoimmune effector cells by a chronic contact eczema. J Immunol 2007; 179: 5071.
71. Lees JR, Azimzadeh AM, Bromberg JS. Myeloid derived suppressor cells in transplantation. Curr Opin Immunol 2011; 23: 692.
72. Garcia MR, Ledgerwood L, Yang Y, et al. Monocytic suppressive cells mediate cardiovascular transplantation tolerance in mice. J Clin Invest 2010; 120: 2486.
73. Garrod KR, Chang CK, Liu FC, et al. Targeted lymphoid homing of dendritic cells is required for prolongation of allograft survival. J Immunol 2006; 177: 863.
74. Takayama T, Morelli AE, Onai N, et al. Mammalian and viral IL-10 enhance C-C chemokine receptor 5 but down-regulate C-C chemokine receptor 7 expression by myeloid dendritic cells: Impact on chemotactic responses and in vivo homing ability. J Immunol 2001; 166: 7136.
75. Leishman AJ, Silk KM, Fairchild PJ. Pharmacological manipulation of dendritic cells in the pursuit of transplantation tolerance. Curr Opin Organ Transplant 2011; 16: 372.
76. Taner T, Hackstein H,Wang Z, et al. Rapamycin-Treated, alloantigenpulsed host dendritic cells induce Ag-specific T cell regulation and prolong graft survival. Am J Transplant 2005; 5: 228.
77. Peche H, Trinite B, Martinet B, et al. Prolongation of heart allograft survival by immature dendritic cells generated from recipient type bone marrow progenitors. Am J Transplant 2005; 5: 255.
78. Reichardt W, Durr C, von Elverfeldt D, et al. Impact of mammalian target of rapamycin inhibition on lymphoid homing and tolerogenic function of nanoparticle-labeled dendritic cells following allogeneic hematopoietic cell transplantation. J Immunol 2008; 181: 4770.
79. Emmer PM, van der Vlag J, Adema GJ, et al. Dendritic cells activated by lipopolysaccharide after dexamethasone treatment induce donorspecific allograft hyporesponsiveness. Transplantation 2006; 81: 1451.
80. Ridolfi R, Riccobon A, Galassi R, et al. Evaluation of in vivo labelled dendritic cell migration in cancer patients. J Transl Med 2004; 2: 27.
81. Huang B, Lei Z, Zhao J, et al. CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers. Cancer Lett 2007; 252: 86.
82. Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol 2008; 9: 1225.
83. Wang H, Arp J, Liu W, et al. Inhibition of terminal complement components in presensitized transplant recipients prevents antibody-mediated rejection leading to long-Term graft survival and accommodation. J Immunol 2007; 179: 4451.
84. Ezernitchi AV, Vaknin I, Cohen-Daniel L, et al. TCR zeta downregulation under chronic inflammation is mediated by myeloid suppressor cells differentially distributed between various lymphatic organs. J Immunol 2006; 177: 4763.
85. Dugast AS, Haudebourg T, Coulon F, et al. Myeloid-derived suppressor cells accumulate in kidney allograft tolerance and specifically suppress effector T cell expansion. J Immunol 2008; 180: 7898.
86. Dilek N, Poirier N, Usal C, et al. Control of transplant tolerance and intragraft regulatory T cell localization by myeloid-derived suppressor cells and CCL5. J Immunol 2012; 188: 4209.
87. Hock BD, Mackenzie KA, Cross NB, et al. Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. Nephrol Dial Transplant 2012; 27: 402.
88. Zheng G, Zhong S, Geng Y, et al. Dexamethasone promotes tolerance in vivo by enriching CD11clo CD40lo tolerogenic macrophages. Eur J Immunol 2013; 43: 219.
89. Zhang K, Bai X, Li R, et al. Endogenous glucocorticoids promote the expansion of myeloid-derived suppressor cells in a murine model of trauma. Int J Mol Med 2012; 30: 277.
90. Adorini L, Penna G. Induction of tolerogenic dendritic cells by vitamin D receptor agonists. Handb Exp Pharmacol 2009; 251.
91. Pedersen AW, Claesson MH, Zocca MB. Dendritic cells modified by vitamin D: Future immunotherapy for autoimmune diseases. Vitam Horm 2011; 86: 63.
92. Young MR, Lozano Y, Ihm J, et al. Vitamin D3 treatment of tumor bearers can stimulate immune competence and reduce tumor growth when treatment coincides with a heightened presence of natural suppressor cells. Cancer Lett 1996; 104: 153.
93. Prechel MM, Lozano Y, Wright MA, et al. Immune modulation by interleukin-12 in tumor-bearing mice receiving vitamin D3 treatments to block induction of immunosuppressive granulocyte/ macrophage progenitor cells. Cancer Immunol Immunother 1996; 42: 213.
94. Wiers K,Wright MA, Vellody K, et al. Failure of tumor-reactive lymph node cells to kill tumor in the presence of immune-suppressive CD34+ cells can be overcome with vitamin D3 treatment to diminish CD34+ cell levels. Clin Exp Metastasis 1998; 16: 275.
95. Knight SC, Roberts M, Macatonia SE, et al. Blocking of acquisition and presentation of antigen by dendritic cells with cyclosporine. Studies with fluorescein isothiocyanate. Transplantation 1988; 46: 48S.
96. Damoiseaux JG, Beijleveld LJ, van Breda Vriesman PJ. Quantification and phenotypic characterization of the rat thymic dendritic cell population upon in vivo cyclosporine administration. Transplant Proc 1993; 25: 2814.
97. Rezzani R, Rodella L, Corsetti G, et al. Effects of cyclosporin A on some accessory cells of rat thymus. Int J Exp Pathol 1995; 76: 247.
98. De Waal EJ, Rademakers LH, Schuurman HJ, et al. Alterations of dendritic cells in the rat thymus without epithelial cell loss during cyclosporine treatment and recovery. Toxicology 1996; 110: 133.
99. Li J, Chen G, Ye P, et al. CCR5 blockade in combination with cyclosporine increased cardiac graft survival and generated alternatively activatedmacrophages in primates. J Immunol 2011; 186: 3753.
100. Barten MJ, Garbade J, Bittner HB, et al. Affects of immunosuppression on circulating dendritic cells: An adjunct to therapeutic drug monitoring after heart transplantation. Int Immunopharmacol 2006; 6: 2011.
101. Tourneur E, Ben Mkaddem S, Chassin C, et al. Cyclosporine A impairs nucleotide binding oligomerization domain (Nod1)-mediated innate antibacterial renal defenses in mice and human transplant recipients. PLoS Pathog 2013; 9: E1003152.
102. Lee YH, Lee YR, Im SA, et al. Calcineurin inhibitors block MHCrestricted antigen presentation in vivo. J Immunol 2007; 179: 5711.
103. Jennings C, Kusler B, Jones PP. Calcineurin inactivation leads to decreased responsiveness to LPS in macrophages and dendritic cells and protects against LPS-induced toxicity in vivo. Innate Immun 2009; 15: 109.
104. Setkowicz Z, Caryk M, Szafraniec M, et al. Tacrolimus (FK506) and cyclosporin A reduce macrophage recruitment to the rat brain injured at perinatal and early postnatal periods. Neurol Res 2009; 31: 1060.
105. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001; 107: 519.
106. Fischer R, Turnquist HR, Taner T, et al. Use of rapamycin in the induction of tolerogenic dendritic cells. Handb Exp Pharmacol 2009; (188): 215.
107. Woltman AM, de Fijter JW, Kamerling SW, et al. Rapamycin induces apoptosis in monocyte-And CD34-derived dendritic cells but not in monocytes and macrophages. Blood 2001; 98: 174.
108. Haidinger M, Poglitsch M, Geyeregger R, et al. A versatile role of mammalian target of rapamycin in human dendritic cell function and differentiation. J Immunol 2010; 185: 3919.
109. Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. J Immunol 2000; 165: 2374.
110. Jiang S, Tang Q, Rong R, et al. Mycophenolate mofetil inhibits macrophage infiltration and kidney fibrosis in long-Term ischemiareperfusion injury. Eur J Pharmacol 2012; 688: 56.
111. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest 2008; 118: 2562.
112. SongW, Tai YT, Tian Z, et al. HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells. Leukemia 2011; 25: 161.
113. Zinser E, Rossner S, Littmann L, et al. Inhibition of the proteasome influences murine and human dendritic cell development in vitro and in vivo. Immunobiology 2009; 214: 843.
114. Iwamoto S, Azuma E, Kumamoto T, et al. Efficacy of azithromycin in preventing lethal graft-versus-host disease. Clin Exp Immunol 2013; 171: 338.
115. Vos IH, Govers R, Grone HJ, et al. NFkappaB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000; 14: 815.
116. Ogawa M, Suzuki J, Kosuge H, et al. The mechanism of antiinflammatory effects of prostaglandin E2 receptor 4 activation in murine cardiac transplantation. Transplantation 2009; 87: 1645.
117. Fang L, Fehse B, Engel M, et al. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79: 369.
118. Kirsch BM, Haidinger M, Zeyda M, et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006; 16: 254.
119. Guillot C, Menoret S, Guillonneau C, et al. Active suppression of allogeneic proliferative responses by dendritic cells after induction of long-Term allograft survival by CTLA4Ig. Blood 2003; 101: 3325.
120. Niimi M, Shirasugi N, Ikeda Y, et al. Operational tolerance induced by pretreatment with donor dendritic cells under blockade of CD40 pathway. Transplantation 2001; 72: 1556.
121. Zhang X, Beduhn M, Zheng X, et al. Induction of alloimmune tolerance in heart transplantation through gene silencing of TLR adaptors. Am J Transplant 2012; 12: 2675.
122. Adeegbe D, Serafini P, Bronte V, et al. In vivo induction of myeloid suppressor cells and CD4(+)Foxp3(+) T regulatory cells prolongs skin allograft survival in mice. Cell Transplant 2011; 20: 941.
123. Abe M, Thomson AW. Influence of immunosuppressive drugs on dendritic cells. Transpl Immunol 2003; 11: 357.
124. Svajger U, Obermajer N, Jeras M. Novel findings in drug-induced dendritic cell tolerogenicity. Int Rev Immunol 2010; 29: 574.
125. Kooten C, Stax AS, Woltman AM, et al. Handbook of Experimental Pharmacology 'Dendritic Cells'. In: Lombardi G, Riffo-Vasquez Y, eds. Berlin/Heidelberg: Springer; 2013.
126. Piemonti L, Monti P, Allavena P, et al. Glucocorticoids affect human dendritic cell differentiation and maturation. J Immunol 1999; 162: 6473.
127. Varga G, Ehrchen J, Tsianakas A, et al. Glucocorticoids induce an activated, anti-inflammatory monocyte subset in mice that resembles myeloid-derived suppressor cells. J Leukoc Biol 2008; 84: 644.
128. Gustafson MP, Lin Y, New KC, et al. Systemic immune suppression in glioblastoma: The interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone. Neuro Oncol 2010; 12: 631.
129. Lee YR, Yang IH, Lee YH, et al. Cyclosporin A and tacrolimus, but not rapamycin, inhibit MHC-restricted antigen presentation pathways in dendritic cells. Blood 2005; 105: 3951.
130. Ma A, Qi S, Xu D, et al. Immunological evaluation of combination therapy with tacrolimus and sirolimus on long-Term allograft survival in nonhuman primates. Transplant Proc 2005; 37: 150.
131. Tajima K, Amakawa R, Ito T, et al. Immunomodulatory effects of cyclosporin A on human peripheral blood dendritic cell subsets. Immunology 2003; 108: 321.
132. Kim YS, Kim YJ, Lee JM, et al. Functional changes in myeloid-derived suppressor cells (MDSCs) during tumor growth: FKBP51 contributes to the regulation of the immunosuppressive function of MDSCs. J Immunol 2012; 188: 4226.
133. Fric J, Lim CX, Koh EG, et al. Calcineurin/NFAT signalling inhibits myeloid haematopoiesis. EMBO Mol Med 2012; 4: 269.
134. Fulton B, Markham A. Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation. Drugs 1996; 51: 278.
135. Colic M, Stojic-Vukanic Z, Pavlovic B, et al. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003; 134: 63.
136. Cicinnati VR, Hou J, Lindemann M, et al. Mycophenolic acid impedes the antigen presenting and lymph node homing capacities of human blood myeloid dendritic cells. Transplantation 2009; 88: 504.
137. Lagaraine C, Hoarau C, Chabot V, et al. Mycophenolic acid-Treated human dendritic cells have a mature migratory phenotype and inhibit allogeneic responses via direct and indirect pathways. Int Immunol 2005; 17: 351.
138. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369.
139. Battaglia M, Stabilini A, Migliavacca B, et al. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006; 177: 8338.
140. Horibe EK, Sacks J, Unadkat J, et al. Rapamycin-conditioned, alloantigen-pulsed dendritic cells promote indefinite survival of vascularized skin allografts in association with T regulatory cell expansion. Transpl Immunol 2008; 18: 307.
141. Weichhart T, Haidinger M, Katholnig K, et al. Inhibition of mTOR blocks the anti-inflammatory effects of glucocorticoids in myeloid immune cells. Blood 2011; 117: 4273.
142. Turnquist HR, Cardinal J, Macedo C, et al. mTOR and GSK-3 shape the CD4+ T cell stimulatory and differentiation capacity of myeloid DC following exposure to LPS. Blood 2010; 115: 4758.
143. Macedo C, Turnquist HR, Castillo-Rama M, et al. Rapamycin augments human DC IL-12p70 and IL-27 secretion to promote allogeneic Type 1 polarization modulated by NK cells. Am J Transplant 2013; 13: 2322.
144. Sathaliyawala T, O'Gorman WE, Greter M, et al. Mammalian target of rapamycin controls dendritic cell development downstream of Flt3 ligand signaling. Immunity 2010; 33: 597.
145. Frikeche J, Simon T, Brissot E, et al. Impact of valproic acid on dendritic cells function. Immunobiology 2012; 217: 704.
146. Sebastian C, Serra M, Yeramian A, et al. Deacetylase activity is required for STAT5-dependent GM-CSF functional activity in macrophages and differentiation to dendritic cells. J Immunol 2008; 180: 5898.
147. Wang Y, Camirand G, Lin Y, et al. Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice. J Immunol 2011; 186: 2809.
148. Wu C, Li A, Leng Y, et al. Histone deacetylase inhibition by sodium valproate regulates polarization of macrophage subsets. DNA Cell Biol 2012; 31: 592.
149. Rosborough BR, Castellaneta A, Natarajan S, et al. Histone deacetylase inhibition facilitates GM-CSF-mediated expansion of myeloid-derived suppressor cells in vitro and in vivo. J Leukoc Biol 2012; 91: 701.
150. Subklewe M, Sebelin-Wulf K, Beier C, et al. Dendritic cell maturation stage determines susceptibility to the proteasome inhibitor bortezomib. Hum Immunol 2007; 68: 147.
151. Vodanovic-Jankovic S, Hari P, Jacobs P, et al. NF-kappaB as a target for the prevention of graft-versus-host disease: Comparative efficacy of bortezomib and PS-1145. Blood 2006; 107: 827.
152. Sun K, Welniak LA, Panoskaltsis-Mortari A, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-Tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A 2004; 101: 8120.
153. Nencioni A, Garuti A, Schwarzenberg K, et al. Proteasome inhibitorinduced apoptosis in human monocyte-derived dendritic cells. Eur J Immunol 2006; 36: 681.
154. Min WP, Zhou D, Ichim TE, et al. Inhibitory feedback loop between tolerogenic dendritic cells and regulatory T cells in transplant tolerance. J Immunol 2003; 170: 1304.
155. Yang J, Bernier SM, Ichim TE, et al. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J Leukoc Biol 2003; 74: 438.
156. Zeyda M, Kirsch BM, Geyeregger R, et al. Inhibition of human dendritic cell maturation and function by the novel immunosuppressant FK778. Transplantation 2005; 80: 1105.
157. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol 2011; 32: 19.
158. Fujita M, Kohanbash G, Fellows-Mayle W, et al. COX-2 blockade suppresses gliomagenesis by inhibiting myeloid-derived suppressor cells. Cancer Res 2011; 71: 2664.
159. Ma N, Szabolcs MJ, Sun J, et al. The effect of selective inhibition of cyclooxygenase (COX)-2 on acute cardiac allograft rejection. Transplantation 2002; 74: 1528.
160. Naujokat C, Berges C, Fuchs D, et al. Antithymocyte globulins suppress dendritic cell function by multiple mechanisms. Transplantation 2007; 83: 485.
161. Gillet-Hladky S, de Carvalho CM, Bernaud J, et al. Rabbit antithymocyte globulin inhibits monocyte-derived dendritic cells maturation in vitro and polarizes monocyte-derived dendritic cells towards tolerogenic dendritic cells expressing indoleamine 2,3-dioxygenase. Transplantation 2006; 82: 965.
162. Buggins AG, Mufti GJ, Salisbury J, et al. Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab. Blood 2002; 100: 1715.
163. Auffermann-Gretzinger S, Eger L, Schetelig J, et al. Alemtuzumab depletes dendritic cells more effectively in blood than in skin: A pilot study in patients with chronic lymphocytic leukemia. Transplantation 2007; 83: 1268.
164. Mnasria K, Lagaraine C, Manaa J, et al. Anti CD25 treatment of human dendritic cells modulates both their cytokine synthesis profiles and their capacity to activate allogeneic CD4 T cells: A potential tolerogenic effect. Int Immunopharmacol 2008; 8: 414.
165. Mnasria K, Lagaraine C, Velge-Roussel F, et al. Anti-CD25 antibodies decrease the ability of human dendritic cells to prime allogeneic CD4 T cells. Transplant Proc 2009; 41: 695.
166. Wuest SC, Edwan JH, Martin JF, et al. A role for interleukin-2 transpresentation in dendritic cell-mediated T cell activation in humans, as revealed by daclizumab therapy. Nat Med 2011; 17: 604.
167. Medina-Echeverz J, Fioravanti J, Zabala M, et al. Successful colon cancer eradication after chemoimmunotherapy is associated with profound phenotypic change of intratumoral myeloid cells. J Immunol 2011; 186: 807.
168. Pilat N, Schwarz C, Wekerle T. Modulating T-cell costimulation as new immunosuppressive concept in organ transplantation. Curr Opin Organ Transplant 2012; 17: 368.
169. Kinnear G, Jones ND, Wood KJ. Costimulation blockade: Current perspectives and implications for therapy. Transplantation 2013; 95: 527.
170. Grohmann U, Orabona C, Fallarino F, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol 2002; 3: 1097.
171. Mayer E, Holzl M, Ahmadi S, et al. CTLA4-Ig immunosuppressive activity at the level of dendritic cell/T cell crosstalk. Int Immunopharmacol 2013; 15: 638.
172. Liu Y, Yu Y, Yang S, et al. Regulation of arginase I activity and expression by both PD-1 and CTLA-4 on the myeloid-derived suppressor cells. Cancer Immunol Immunother 2009; 58: 687.
173. Aoyagi T, Yamashita K, Suzuki T, et al. A human anti-CD40monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys: Induction and maintenance therapy. Am J Transplant 2009; 9: 1732.
174. Pearson TC, Trambley J, Odom K, et al. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74: 933.
175. Fu W, Zhu J, Qiu Y, et al. Induction of CD4+CD25+ T cells and control of cardiac allograft rejection by CD40/CD40L costimulatory pathway blockade in mice. Transplant Proc 2013; 45: 611.
176. Luyckx A, Schouppe E, Rutgeerts O, et al. G-CSF stem cell mobilization in human donors induces polymorphonuclear and mononuclear myeloid-derived suppressor cells. Clin Immunol 2012; 143: 83.